找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Biologic and Systemic Agents in Dermatology; Paul S. Yamauchi Book 2018 Springer International Publishing AG 2018 systemic dermatology.bio

[復制鏈接]
樓主: Encomium
41#
發(fā)表于 2025-3-28 17:15:43 | 只看該作者
Kinderarmut in Ost- und Westdeutschlandeasurements of humanistic outcomes or clinical efficacy, such as utility scores, patient-reported outcomes, and number needed to treat. Finally, we present an example of a cost analysis for biologic agents in the treatment of psoriasis to emphasize the importance of pharmacoeconomic considerations in daily clinical practice for dermatologists.
42#
發(fā)表于 2025-3-28 20:55:47 | 只看該作者
Kinderarmut in der WohlfahrtsgesellschaftIL-17A and other pro-inflammatory cytokines drive keratinocyte activation and hyperproliferation in psoriasis. This review will focus on the role of IL-23 in psoriasis pathogenesis and the therapeutic targeting of IL-23 by monoclonal antibodies in patients with psoriasis.
43#
發(fā)表于 2025-3-28 22:57:15 | 只看該作者
Outcome Measures in Psoriasis and Atopic Eczema,c dermatitis studies, important measures include the Eczema Area and Severity Index (EASI), the SCORAD, and the IGA. This chapter focuses on the most commonly used and the most psychometrically valid efficacy measures in clinical trials for psoriasis and eczema.
44#
發(fā)表于 2025-3-29 03:31:49 | 只看該作者
45#
發(fā)表于 2025-3-29 07:55:29 | 只看該作者
Dual Inhibition of IL-12/IL-23 and Selective Inhibition of IL-23 in Psoriasis,IL-17A and other pro-inflammatory cytokines drive keratinocyte activation and hyperproliferation in psoriasis. This review will focus on the role of IL-23 in psoriasis pathogenesis and the therapeutic targeting of IL-23 by monoclonal antibodies in patients with psoriasis.
46#
發(fā)表于 2025-3-29 15:13:23 | 只看該作者
Book 2018the clinical data, as well as practical tips on how to use both biologic and systemic agents in the field of dermatology. In the past decade, there have been several groundbreaking advances in medical dermatology. Novel biologic and systemic agents have been developed to treat inflammatory disorders
47#
發(fā)表于 2025-3-29 15:40:12 | 只看該作者
48#
發(fā)表于 2025-3-29 20:16:53 | 只看該作者
49#
發(fā)表于 2025-3-30 01:52:09 | 只看該作者
50#
發(fā)表于 2025-3-30 04:16:32 | 只看該作者
 關于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結 SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-16 10:04
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權所有 All rights reserved
快速回復 返回頂部 返回列表
芦溪县| 衡山县| 盖州市| 屏东市| 邢台县| 长治市| 山丹县| 嘉峪关市| 黔西县| 福州市| 府谷县| 信丰县| 嘉黎县| 民丰县| 集安市| 黄梅县| 元谋县| 康马县| 米易县| 澄城县| 衡南县| 乌苏市| 满城县| 双鸭山市| 河南省| 贵溪市| 囊谦县| 萨迦县| 新沂市| 汾西县| 黄龙县| 利辛县| 迁安市| 华亭县| 佳木斯市| 隆回县| 溆浦县| 噶尔县| 康乐县| 安溪县| 上饶县|